Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.97, Iss.2, 2006-05, pp. : 223-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet

Molecular Medicine Reports, Vol. 5, Iss. 1, 2012-01 ,pp. : 37-40

Spandidos Publications

Access to resources Recommend Favorite

Adjuvant bisphosphonates in breast cancer: has the time come?

By Gagliato Debora Chavez-MacGregor Mariana

Breast Cancer Management, Vol. 2, Iss. 4, 2013-07 ,pp. : 327-337

Future Medicine

Access to resources Recommend Favorite

Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice

Molecular Medicine Reports, Vol. 12, Iss. 5, 2015-01 ,pp. : 6895-6902

Spandidos Publications

Access to resources Recommend Favorite

Has the Time Come for Routine Use of Amifostine in Clinical Radiotherapy Practice?

By Lindegaard Jacob Ch r.

Acta Oncologica, Vol. 42, Iss. 1, 2003-01 ,pp. : 2-3

Informa Healthcare

Access to resources Recommend Favorite

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

Molecular Medicine Reports, Vol. 11, Iss. 3, 2015-01 ,pp. : 1693-1700

Spandidos Publications

Access to resources Recommend Favorite